重组人 p53基因腺病毒注射液在原发性肝癌介入治疗中的临床研究

摘要

目的：研究重组人 p53腺病毒注射液（商品名：今又生）在原发性肝癌介入治疗中的安全性及有效性。方法：61例中晚期原发性肝癌患者，分两组介入治疗：对照组：碘油＋化疗药（5－FU ＋EPI ＋DDP）；治疗组：碘油＋化疗药（5－FU ＋EPI ＋DDP）＋重组人 p53基因腺病毒注射液；每4周一次，连用3次。结果：不论是对照组还是治疗组，毒副反应不大，耐受性良好，生活质量均有一定的提高；治疗后两组均能使原发性肝癌的肿瘤标志物 AFP 下降，但治疗组下降明显；治疗组的有效率（82．76％）明显高于对照组（59．38％），统计学检验差异显著。结论：今又生介入治疗原发性肝癌安全有效，值得推广。%Objective:To study the efficacy and safety of restructuring of p53 adenovirus injecttion in the primary liver cancer underwenttranscatheter arterial chemoembolization,TACE.Methods:Sixty one patients were diagnosed as primary liver cancer,pathologically.All patients underwent transcatheter arterial chemoembolization,TACE and were randomized divided into two groups,the control group was treated by iodine oil +chemotherapy drugs(5 -FU +EPI +DDP),the treatment group withiodine oil +chemotherapy drugs(5 -FU +EPI +DDP)+restructuring of p53 adenovi-rus injection.The efficacy,quality of life(QOL),and adverse reactions were evaluated.Results:In two groups,the re-liability safety was similar,life quality was enhanced,and the tumor mark was decinling.The effective rates of two groups were 59.38% and 82.76%,the treatment group was superior to the control group(P <0.05).Conclusion:U-sing restructuring of p53 adenovirus injectionon the interventional therapyin the primary liver cancer,can increase ef-fective rate.